Literature DB >> 31635968

Infection in cirrhosis: A prospective study.

Chandramouli Bhattacharya1, Manisha Das-Mondal2, Debkishore Gupta3, Ajoy K Sarkar4, Sujit Kar-Purkayastha2, Asokananda Konar2.   

Abstract

INTRODUCTION AND
OBJECTIVES: Multidrug-resistant (MDR) infections in cirrhosis are associated with poor outcomes. We attempted a prospective study on infections in patients with cirrhosis evaluating microbiology of these infections and how outcomes depended on factors like bacterial resistance, appropriate antibiotics, stage of liver disease and whether outcomes were significantly different from patients who did not have infections.
MATERIALS AND METHODS: This was a prospective evaluation involving one hundred and fifty nine patients with cirrhosis who were admitted at Peerless Hospitex Hospital and Research Center, Kolkata, West Bengal, India, during a 24 month period. One hundred and nineteen of these patients either had an infection at the time of admission or developed infection during hospitalization. Forty patients did not have an infection at admission and did not acquire infection while admitted. Data was collected about demographics, etiology of cirrhosis, liver and renal function and microbiology.
RESULTS: Infections were community acquired in 27.7% of patients, healthcare associated in 52.9% and nosocomial in 19.3%. Gram negative bacilli (Escherichia coli 47.4% Klebsiella pneumoniae 23%) were common. 84.9% of enterobacteriaceae produced ESBL, AmpC or Carbapenemases. Spontaneous bacteria peritonitis (SBP) and urinary tract infection (UTI) were the most common sites of infection. In hospital mortality was 21.9%. Non-survivors had higher MELD (26 vs 19, p<0.001) and CTP scores (11.7 vs 10.3, p<0.001). The control group had lower MELD (16.65 vs. 20.8, p<0.001) and CTP scores (9.25 vs 10.59, p<0.001).
CONCLUSIONS: MDR infections are common in patients with cirrhosis and have serious implications for treatment and outcomes.
Copyright © 2019 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Antibiotic selection; MELD; Mortality; Multi drug resistant; Nosocomial

Year:  2019        PMID: 31635968     DOI: 10.1016/j.aohep.2019.07.010

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  3 in total

1.  Gut dysbiosis and body composition in cirrhosis.

Authors:  Roman Maslennikov; Vladimir Ivashkin; Aliya Alieva; Elena Poluektova; Anna Kudryavtseva; George Krasnov; Maria Zharkova; Yuri Zharikov
Journal:  World J Hepatol       Date:  2022-06-27

2.  Decompensation of Cirrhosis: An Unusual Cause.

Authors:  Omkar S Rudra; Sherna Menezes; Aabha Nagral
Journal:  Cureus       Date:  2022-05-09

3.  Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis.

Authors:  Roman Maslennikov; Vladimir Ivashkin; Irina Efremova; Aliya Alieva; Ekaterina Kashuh; Ekaterina Tsvetaeva; Elena Poluektova; Elena Shirokova; Konstantin Ivashkin
Journal:  World J Hepatol       Date:  2021-05-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.